Marina N Sharifi

Assistant Professor

University of Wisconsin-Madison
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (19)

Year:

2025

The development of treatment resistance remains universal for patients with metastatic prostate cancer, driven by androgen receptor alterations and lineage state transitions. Identifying the evolution of lineage transitions in treatment resistance has been limited by the challenges of collecting serial tissue biopsies on treatment, which can be overcome using blood-based liquid biopsies. Using a novel circulating tumor cell (CTC) isolation approach, we collected 273 CTC samples from 117 patients with metastatic prostate cancer for RNA sequencing. One hundred forty-six samples from 70 patients had tumor purity comparable with tissue biopsies. We identified four CTC transcriptional phenotypes, mirroring lineage states identified in the tissue. Patients with a luminal-B–like CTC phenotype defined by persistent androgen receptor signaling and high proliferation, as well as those with a neuroendocrine CTC phenotype, had significantly shorter survival than patients with luminal-A–like and low proliferation phenotypes. In a prospective substudy, pretreatment CTC luminal-B–like phenotype was associated with early progression on 177Lu–PSMA-617. Significance: Treatment resistance remains a universal driver of lethal metastatic prostate cancer, associated with acquired genomic alterations and lineage transitions. Using a novel high-purity CTC isolation approach for CTC transcriptional profiling, we identified four lineage phenotypes differentially associated with prognosis in metastatic prostate cancer.

Year:

2025

Metastatic castration‐resistant prostate cancer (mCRPC) is a heterogeneous disease. Several studies have identified transcriptional subtypes of mCRPC, but comprehensive analysis of prognostic gene expression pathways has been limited. Therefore, we aggregated a cohort of 1012 mCRPC tissue samples from 769 patients and investigated the association of gene expression‐based pathways with clinical outcomes and intrapatient and intratumor heterogeneity. Survival data were obtained for 272 patients. Pathway‐level enrichment was evaluated using gene set variation analysis. scRNA‐seq datasets from mCRPC tissue biopsies and circulating tumor cells were used to investigate heterogeneity of adverse pathways. We identified five pathway clusters: (a) Immune response/WNT/TGF‐beta signaling, (b) AR signaling/luminal signatures, (c) mTOR signaling and glycolysis, (d) cell proliferation, and (e) neuroendocrine differentiation. Proliferation, AR signaling loss, and glycolysis/mTOR signaling were independently prognostic. Adverse prognostic pathway scores decreased on treatment with AR signaling inhibitors, but not at progression, suggesting failure to permanently target these pathways. scRNA‐seq datasets from mCRPC tissue biopsies and circulating tumor cells were used to investigate heterogeneity of adverse pathways. Our results suggest loss of AR signaling, high proliferation, and a glycolytic phenotype as adverse prognostic pathways in mCRPC that could be used in conjunction with clinical factors to prognosticate for treatment decisions.

Year:

2025

Background Androgen receptor pathway inhibitors (ARPIs) have significantly improved clinical outcomes for patients with metastatic prostate cancer (PC) but acquired ARPI resistance remains universal. Maximizing ARPI treatment duration is crucial to optimal clinical outcomes, but current clinical tools to detect acquired ARPI resistance, including serum Prostate Specific Antigen (PSA) and radiographic disease monitoring, are limited in both sensitivity and specificity. Since prostate cancer disease progression is associated with an increase in systemic inflammation, we hypothesized that circulating monocytes and monocyte‐derived macrophages (MDMs) in patients with PC would express an increased pro‐inflammatory phenotype in the context of disease progression. Methods Monocytes and MDMs were isolated from peripheral blood samples from 16 patients with PC who were receiving ARPI therapies and performed transcriptomic and functional analysis both alone and in ex vivo coculture with prostate tumor cells utilizing a novel microscale coculture platform. Results We identified a pro‐inflammatory transcriptional signature in MDMs cultured with tumor cells that was associated with current, recent, and impending disease progression. Furthermore, we found that the pro‐inflammatory phenotype of MDMs derived from patients with clinical progression was associated with paracrine anti‐tumorigenic signaling that sensitized tumor cells to ARPI treatment in vitro. Finally, a transcriptional score generated from the MDM transcriptional signature of progressing patients could accurately identify current treatment response status as well as patients with recent/impending changes in response status. Conclusions Disease progression in patients with prostate cancer receiving ARPI therapy is associated with a pro‐inflammatory gene signature in peripheral monocyte‐derived macrophages. We were able to develop a scoring signature based on this pro‐inflammatory gene signature that has the potential to identify patients with recent and impending changes in disease response status that is not detectable using conventional disease assessment criteria. Further research will be needed to validate these findings.

Year:

2025

Introduction The 11th Annual 2024 Coffey ‐ Holden Prostate Cancer Academy (CHPCA) Meeting, was themed “Personalized Medicine: Leave No Patient Behind,” and was held from June 20 to 23, 2024 at the University of California, Los Angeles, Luskin Conference Center, in Los Angeles, CA. Methods The CHPCA Meeting is an academy‐styled annual conference organized by the Prostate Cancer Foundation, to focus discussion on the most critical emerging research that have the greatest potential to advance knowledge of prostate cancer biology and treatment. The 2024 CHPCA Meeting was attended by 75 academic investigators and included 37 talks across 8 sessions. Results The meeting sessions focused on: novel human, mouse and systems biology research models, novel immunotherapies for prostate cancer, efforts to overcome treatment resistance, the role of metabolism and diet in prostate cancer biology and as a therapeutic target, mechanisms that drive differentiation into neuroendocrine cancer subtypes, the evolving prostate cancer epigenome in disease progression and treatment resistance, and machine learning and advanced computational approaches for precision oncology. Discussion This article summarizes the presentations and discussions from the 2024 CHPCA Meeting. We hope that sharing this knowledge will inspire and accelerate research into new discoveries and solutions for prostate cancer.

Year:

2025

Fragmentomics based analysis of cell-free DNA (cfDNA) has recently emerged as a method to infer epigenetic and transcriptional data. Many of these reports analyze whole genome sequencing (WGS) which is not readily available clinically. Targeted exon panels are used for clinical cfDNA variant calling. In this report, we conduct an investigation of multiple published fragmentomics methods for WGS, but on cancer exon panels. We find that strategies utilizing normalized depth metrics, as well as all exons present on the panel, generally allow for better prediction of cancer phenotypes across a range of tumor fractions, though other metrics work particularly well in specific applications. Additionally, genes from commercial clinical targeted sequencing panels could be similarly employed for cancer phenotyping with a minimal decrease in performance despite their smaller genomic coverage. These results suggest that fragmentomics-based analysis of cfDNA can utilize targeted sequencing panels and does not necessarily require additional WGS.

Year:

2025

Genome‐wide screens using CRISPR/RNAi can identify new therapeutic vulnerabilities in prostate cancer. In this study, we combine DepMap functional screen data with a large gene expression database ( N = 1012) and clinical outcomes to identify potentially druggable targets. Eight genes ( CYC , CYP51A1 , DHFR , EBP , KIF15 , PPM1D , SQLE , and UMPS ) demonstrated strong dependency in cell lines and were also associated with worse prognosis clinically, representing potential therapeutic targets in metastatic prostate cancer. Four of these ( DHFR , EBP , KIF15 , and PPM1D ) demonstrated higher expression in neuroendocrine prostate cancer. Furthermore, all but one ( KIF15 ) were not significantly decreased from pretreatment to posttreatment, suggesting that they may remain targetable postabiraterone therapy. All eight genes showed evidence of protein expression in prostate cancers or cell lines. These potentially druggable targets associated with prostate cancer cell line dependency and worse clinical outcomes have also demonstrated literature support as potential targets, supporting further research into their potential clinical relevance as therapeutic targets in prostate cancer.

Year:

2025

As cancer cells evade therapeutic pressure and adopt alternate lineage identities not commonly observed in the tissue of origin, they likely adopt alternate metabolic programs to support their evolving demands. Targeting these alternative metabolic programs in distinct molecular subtypes of aggressive prostate cancer may lead to new therapeutic approaches to combat treatment-resistance. We identify the poorly studied metabolic enzyme Oxoglutarate Dehydrogenase-Like (OGDHL), named for its structural similarity to the tricarboxylic acid (TCA) cycle enzyme Oxoglutarate Dehydrogenase (OGDH), as an unexpected regulator of tumor growth, treatment-induced lineage plasticity, and DNA Damage in prostate cancer. While OGDHL has been described as a tumor-suppressor in various cancers, we find that its loss impairs prostate cancer cell proliferation and tumor formation. Loss of OGDHL profoundly alters Androgen Receptor inhibition-induced plasticity, including suppressing the neuroendocrine markers DLL3 and HES6, induces accumulation of the DNA damage response marker ƔH2AX, and reduces nucleotide synthesis. Our data suggest that OGDHL has minimal impact on TCA cycle activity, and that mitochondrial localization is not required for its regulation of prostate cancer plasticity and nucleotide metabolism. Finally, we demonstrate that OGDHL expression is tightly correlated with neuroendocrine differentiation in clinical prostate cancer. These findings underscore the importance of investigating poorly characterized metabolic genes as potential regulators of distinct molecular subtypes of aggressive cancer.

Year:

2025

Cell-surface target expression is variable across CTC phenotypes. A, Heatmap of gene expression of cell-surface targets ordered by clustering in Fig. 1D . B–J, Cell-surface target expression by CTC phenotype for targets associated with prostate adenocarcinoma ( KLK2 , STEAP1 , and STEAP2 ), pan-cancer cell-surface targets expressed in prostate cancer including TACSTD2 (TROP2), ERBB2 (HER2), and tumor immune checkpoint cell-surface protein CD276 (B7H3), as well as targets associated with prostate neuroendocrine differentiation ( DLL3 , CEACAM5 , and SSTR2 ). For patients with multiple CTC samples, the highest purity sample is included (Low_CTC, n = 30; Low_prolif, n = 12; LumA, n = 24; LumB, n = 31; and NE, n = 3). Low_CTC samples are included for reference but not included in statistical comparisons because they are expected to have low/no expression due to low CTC content.

Year:

2025

RNA-seq of high-purity CTCs isolated from patients with metastatic prostate cancer reveals four transcriptional phenotypes. A, Tumor/CTC purity was assessed using the ESTIMATE algorithm in prostate cancer cell line samples ( n = 12, green), CTC samples processed with standard-stringency ( n = 41, blue) or novel high-stringency ( n = 211, orange) method; healthy donor blood samples processed analogous to novel high-stringency CTC samples ( n = 12, pink) and a published dataset of mCRPC tissue biopsies separated by biopsy site ( n = 629, gray). ESTIMATE score is plotted for each sample. B, ESTIMATE tumor fraction (left) and CIBERSORTx immune content (right) scores for standard-stringency ( n = 41, blue) or high-stringency ( n = 211, orange) CTC methods are plotted and compared with prostate cancer cell lines ( n = 12, green). C, Assessment of the number of samples meeting high-purity threshold for standard-stringency vs. high-stringency methods. D, Consensus k -means clustering of single-sample pathway z -scores of 146 high-purity CTC samples from 70 patients with metastatic prostate cancer identifies four distinct clusters. CRPC, castration-resistant prostate cancer.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (28)

Andrew Armstrong

Professor

Duke Cancer Institute

UNITED STATES
View details

Blake Wilde

Assistant Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Grace Blitzer

University of Wisconsin-Madison

UNITED STATES
View details

David A. Quigley

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Joshua Lang

Professor

University of Wisconsin-Madison

UNITED STATES
View details

Scott Tagawa

Weill Cornell Medicine

UNITED STATES
View details

Nan Sethakorn

Assistant Professor

Loyola University Chicago

UNITED STATES
View details

Scot Callahan

University of Wisconsin School of Medicine and Public Health

UNITED STATES
View details

HAMID EMAMEKHOO

University of Wisconsin-Madison

UNITED STATES
View details

Rendong Yang

Associate Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Steven Kregel

Assistant Professor

Loyola University Chicago

UNITED STATES
View details

Shuang G. Zhao

University of Wisconsin-Madison

UNITED STATES
View details

Michael Haffner

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Elisabeth I. Heath

Wayne State University School of Medicine

UNITED STATES
View details

Andrew S. Goldstein

Associate Professor

University of California

UNITED STATES
View details

David Kosoff

University of Wisconsin-Madison

UNITED STATES
View details

Menggang Yu

Professor

University of Michigan

UNITED STATES
View details

Scott M Dehm

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Roni Haas

David Geffen School of Medicine at UCLA

UNITED STATES
View details

Felix Y. Feng

University of California

UNITED STATES
View details

Atish Choudhury

Dana-Farber Cancer Institute

UNITED STATES
View details

Sheena C Kerr

Research Assistant Professor

University of Wisconsin-Madison

UNITED STATES
View details

David Minh

Illinois Institute of Technology

UNITED STATES
View details

Peter S. Nelson

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Heather Christofk

Professor

David Geffen School of Medicine at UCLA

UNITED STATES
View details

Sean Fanning

Associate Professor with Tenure

Loyola University Chicago

UNITED STATES
View details

Rana R. McKay

University of California, San Diego

UNITED STATES
View details

Paul C Boutros

University of California

UNITED STATES
View details